摘要
目的观察前列地尔和还原型谷胱甘肽(GSH)治疗慢性肾功能衰竭(CRF)的疗效。方法选择2015年4月至2017年8月收治的80例CRF患者资料,依照随机数字表法分为传统组、试验组,每组均40例,入选病例都接受血液透析干预,传统组注射GSH,试验组在传统组基础上联合使用前列地尔,两组患者均进行12~24个月随访,检测治疗后0.5、1、1.5、2年末各组患者肾功能指标,并记录各研究终点时各组患者存活情况,在组间加以比较分析。结果随访1.5、2年,试验组存活率依次为87.50%、80.00%,高于传统组的62.50%、52.50%,差异均较为显著,P <0.05。随访1、1.5、2年,试验组患者Hb水平高于同期传统组,e GFR、24 h UP值更低于传统组,均有统计学意义,P <0.05。结论推荐CRF患者长期、有规律性的联合使用前列地尔与GSH,有益于延缓肾功能衰竭进程。
Objective To observe the efficacy of alprolol and reduced glutathione(GSH) in the treatment of chronic renal failure(CRF). Methods The data of 80 CRF patients admitted from April 2015 to August 2017 were selected and divided into the traditional group and the experimental group according to the random number table method, with 40 cases in each group. The selected cases received hemodialysis intervention, and the traditional group was injected with GSH. The experimental group was combined with alprostadil on the basis of the traditional group. Patients in the two groups were followed up for 12-24 months. Renal function indexes of the patients in each group were tested at the end of 0.5, 1, 1.5, and 2 years after treatment, and each study endpoint was recorded. The survival of patients in the group was compared and analyzed between the groups. Results At the end of 1.5 and 2 years of follow-up, the survival rate of the experimental group was 87.50% and 80.00%, which were higher than the 62.50% and 52.50% of the traditional group. The differences were significant, P<0.05. At the end of 1, 1.5, and 2 years of follow-up, the Hb level of the experimental group was higher than that of the traditional group, and the e GFR and 24 h UP values were lower than those of the traditional group, both of which were statistically significant, P<0.05. Conclusion Longterm and regular combined use of Alprostadil and GSH is recommended for patients with CRF, which is beneficial to delay the progression of renal failure.
作者
毛莹莹
MAO Yingying(Huludao Lianshan District People's Hospital,Huludao 125100,China)
出处
《中国医药指南》
2021年第2期69-70,73,共3页
Guide of China Medicine
